| Nov 6 |
MannKind Q3 2024 Earnings Preview
|
| Nov 5 |
MannKind to Present at 2024 UBS Healthcare Conference
|
| Nov 4 |
High Growth Tech Stocks To Watch In November 2024
|
| Nov 4 |
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
|
| Nov 1 |
MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?
|
| Oct 31 |
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
|
| Oct 31 |
First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
|
| Oct 9 |
MannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Pipeline ...
|
| Oct 9 |
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
|
| Oct 7 |
Why MannKind (MNKD) Could Beat Earnings Estimates Again
|
